Scaling RNA Therapeutics Sustainably Using the ECO Synthesis Manufacturing Platform

Why It Matters

The platform addresses the surge in oligonucleotide demand with a greener, cost‑effective process, potentially reshaping RNA drug manufacturing economics and timelines.

Key Takeaways

• Water‑based enzymatic synthesis reduces hazardous waste
• Scalable production from 10 g to 100 g GLP‑grade
• Higher yields than conventional solid‑phase methods
• Supports rapid CMC development for RNA therapeutics
• Enables sustainable, cost‑effective siRNA manufacturing

Pulse Analysis

The RNA therapeutic market is exploding, driven by breakthroughs in siRNA and mRNA medicines for rare diseases and oncology. Traditional solid‑phase oligonucleotide synthesis (SPOS) struggles to keep pace, hampered by low yields, expensive reagents, and significant solvent waste. Industry players are therefore seeking manufacturing paradigms that can meet volume demands while aligning with ESG goals. Codexis’s ECO Synthesis™ platform directly tackles these pain points by replacing organic solvents with water and leveraging engineered enzymes to drive phosphodiester bond formation, dramatically cutting environmental impact and operational costs.

ECO Synthesis™ distinguishes itself through its modular, high‑yield workflow. In a recent demonstration, the platform produced a 10‑gram siRNA batch in a single run and, through its ECO Innovation Lab, can scale to 100 grams of GLP‑grade material for preclinical toxicology. The enzymatic route delivers yields that exceed those of SPOS, translating into fewer reaction cycles and reduced raw material consumption. Moreover, the fully aqueous environment simplifies downstream purification, shortens cycle times, and improves product consistency—critical factors for meeting cGMP standards and accelerating time‑to‑clinic.

For pharmaceutical companies, the implications are profound. A sustainable, high‑throughput siRNA manufacturing solution lowers capital expenditures and per‑dose costs, making RNA therapeutics more accessible to patients and investors. It also streamlines CMC development, as the platform’s reproducibility eases regulatory filings and scale‑up risk. As the pipeline of RNA‑based drugs expands, platforms like ECO Synthesis™ could become the new industry benchmark, driving both environmental stewardship and commercial viability in the next generation of biotech manufacturing.